IRIS Accounts Production v26.2.0.496 12282255 Board of Directors 30.11.25 1.12.24 30.11.25 30.11.25 true true true false true true false false false false false false false false true false Ordinary 0 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 12282255 2024-11-30 12282255 2025-11-30 12282255 2024-12-01 2025-11-30 12282255 2023-11-30 12282255 2023-12-01 2024-11-30 12282255 2024-11-30 12282255 ns15:EnglandWales 2024-12-01 2025-11-30 12282255 ns14:PoundSterling 2024-12-01 2025-11-30 12282255 ns10:Director1 2024-12-01 2025-11-30 12282255 ns10:Consolidated 2025-11-30 12282255 ns10:ConsolidatedGroupCompanyAccounts 2024-12-01 2025-11-30 12282255 ns10:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 12282255 ns10:Consolidated ns10:FRS102 2024-12-01 2025-11-30 12282255 ns10:Consolidated ns10:Audited 2024-12-01 2025-11-30 12282255 ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport 2024-12-01 2025-11-30 12282255 ns10:LargeMedium-sizedCompaniesRegimeForAccounts 2024-12-01 2025-11-30 12282255 ns10:Consolidated ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport 2024-12-01 2025-11-30 12282255 ns10:LargeMedium-sizedCompaniesRegimeForAccounts ns10:Consolidated 2024-12-01 2025-11-30 12282255 ns10:FullAccounts 2024-12-01 2025-11-30 12282255 ns5:Subsidiary1 2024-12-01 2025-11-30 12282255 ns5:Subsidiary2 2024-12-01 2025-11-30 12282255 ns5:Subsidiary3 2024-12-01 2025-11-30 12282255 ns5:Subsidiary4 2024-12-01 2025-11-30 12282255 ns5:Subsidiary5 2024-12-01 2025-11-30 12282255 1 2024-12-01 2025-11-30 12282255 ns10:OrdinaryShareClass1 2024-12-01 2025-11-30 12282255 ns10:Consolidated 2024-12-01 2025-11-30 12282255 ns10:Director2 2024-12-01 2025-11-30 12282255 ns10:RegisteredOffice 2024-12-01 2025-11-30 12282255 ns10:Consolidated 2023-12-01 2024-11-30 12282255 ns5:CurrentFinancialInstruments 2025-11-30 12282255 ns5:CurrentFinancialInstruments 2024-11-30 12282255 ns5:Non-currentFinancialInstruments 2025-11-30 12282255 ns5:Non-currentFinancialInstruments 2024-11-30 12282255 ns5:ShareCapital 2025-11-30 12282255 ns5:ShareCapital 2024-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2025-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2024-11-30 12282255 ns5:ShareCapital 2023-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2023-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2023-12-01 2024-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2024-12-01 2025-11-30 12282255 ns5:NetGoodwill 2024-12-01 2025-11-30 12282255 ns5:OwnedOrFreeholdAssets ns5:LandBuildings 2024-12-01 2025-11-30 12282255 ns5:FurnitureFittings 2024-12-01 2025-11-30 12282255 ns5:MotorVehicles 2024-12-01 2025-11-30 12282255 ns5:NetGoodwill 2024-11-30 12282255 ns5:NetGoodwill 2025-11-30 12282255 ns5:NetGoodwill 2024-11-30 12282255 ns5:LandBuildings 2024-11-30 12282255 ns5:FurnitureFittings 2024-11-30 12282255 ns5:MotorVehicles 2024-11-30 12282255 ns5:LandBuildings 2024-12-01 2025-11-30 12282255 ns5:LandBuildings 2025-11-30 12282255 ns5:FurnitureFittings 2025-11-30 12282255 ns5:MotorVehicles 2025-11-30 12282255 ns5:LandBuildings 2024-11-30 12282255 ns5:FurnitureFittings 2024-11-30 12282255 ns5:MotorVehicles 2024-11-30 12282255 ns5:CostValuation 2024-11-30 12282255 ns5:Subsidiary1 1 2024-12-01 2025-11-30 12282255 3 ns5:Subsidiary2 2024-12-01 2025-11-30 12282255 ns5:Subsidiary3 5 2024-12-01 2025-11-30 12282255 7 ns5:Subsidiary4 2024-12-01 2025-11-30 12282255 9 ns5:Subsidiary5 2024-12-01 2025-11-30 12282255 ns5:CurrentFinancialInstruments ns5:WithinOneYear 2025-11-30 12282255 ns5:CurrentFinancialInstruments ns5:WithinOneYear 2024-11-30 12282255 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2025-11-30 12282255 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2024-11-30 12282255 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-11-30 12282255 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2024-11-30 12282255 ns5:DeferredTaxation 2024-11-30 12282255 ns5:DeferredTaxation 2024-12-01 2025-11-30 12282255 ns5:DeferredTaxation 2025-11-30 12282255 ns10:OrdinaryShareClass1 2025-11-30 12282255 ns5:RetainedEarningsAccumulatedLosses 2024-11-30

REGISTERED NUMBER: 12282255 (England and Wales)

Group Strategic Report, Report of the Directors and

Consolidated Financial Statements for the Year Ended 30 November 2025

for

LP Healthcare Limited

LP Healthcare Limited (Registered number: 12282255)

Contents of the Consolidated Financial Statements

for the Year Ended 30 November 2025

Page |

Company Information | 1 |

Group Strategic Report | 2 |

Report of the Directors | 3 |

Report of the Independent Auditors | 4 |

Consolidated Income Statement | 7 |

Consolidated Other Comprehensive Income | 8 |

Consolidated Balance Sheet | 9 |

Company Balance Sheet | 10 |

Consolidated Statement of Changes in Equity | 11 |

Company Statement of Changes in Equity | 12 |

Consolidated Cash Flow Statement | 13 |

Notes to the Consolidated Cash Flow Statement | 14 |

Notes to the Consolidated Financial Statements | 15 |

LP Healthcare Limited

Company Information

for the Year Ended 30 November 2025

| DIRECTORS: | Mrs K L Rogerson

| Mr P J Rogerson

| REGISTERED OFFICE: | 19 Park Street

| Lytham

| Lancashire

| FY85LU

| REGISTERED NUMBER: | 12282255 (England and Wales)

| AUDITORS: | Ashworth Treasure Limited

| Statutory Auditors

| 17-19 Park Street

| Lytham

| Lancashire

| FY8 5LU

LP Healthcare Limited (Registered number: 12282255)

Group Strategic Report

for the Year Ended 30 November 2025

The directors present their strategic report of the company and the group for the year ended 30 November 2025.

REVIEW OF BUSINESS

The directors are satisfied with the results for the year and continue to pursue a growth strategy that combines organic expansion with acquisitions of existing homes. The company continues to invest in the maintenance and enhancement of existing homes.

Key performance indicators

Turnover and profits

Group turnover has increased by 14% to £7,274,646 and profits before tax increased from £722,972 to £1,192,755 with the group maintaining strong cash reserves at the end of the year.

Gross profit for the year was £3,478,666 (2024: £2,968,803) an increase of 17% year-on-year.

The profit after taxation for the year amounted to £742,291 (2024: £446,928).

Borrowing and liquidity

Borrowing increased in the year from £5,934,171 in 2024 to £6,795,042 in 2025 in order to finance the extension of a nursing home. The liquidity ratio improved from 206% in 2024 to 303% in 2025.

Occupancy

Target occupancy levels are 95%. The average levels achieved in 2025 were 94% (2024: 95%).

PRINCIPAL RISKS AND UNCERTAINTIES

The principle risk for the business would be a poor report from its regulators, this risk is mitigated by the groups commitment to the provision of exceptional care in each home it operates with constant monitoring and investment in employee training.

Financial operating risks to the business in recent and future years continue to be rising staff costs due to minimum wages increases and agency reliance because of workforce availability. Also, dependence on local authority or NHS funding which may be constrained and risk of changes in government funding models or fee caps. These are monitored with good budgeting, staff rota management and payment policies.

Rising costs due to inflation,especially in energy, food, wages and lending interest rates all pose a risk to the profitability and repayment of debt.

The group is well placed and maintains a strategy of strong management and leadership which enable the companies to react quickly to any future risks or uncertainties.

FUTURE DEVELOPMENTS

The directors remain committed to providing high-quality residential and nursing care across all its facilities. In the coming year, the group plans to undertake a programme of investment in its properties including an extension at one of the homes in order to increase occupancy levels.

Recruitment and retention of skilled care staff remains a priority. The group will expand its in-house training programmes and continue to invest in staff to address sector-wide workforce challenges.

ON BEHALF OF THE BOARD:

Mrs K L Rogerson - Director

26 August 2026

LP Healthcare Limited (Registered number: 12282255)

Report of the Directors

for the Year Ended 30 November 2025

The directors present their report with the financial statements of the company and the group for the year ended 30 November 2025.

PRINCIPAL ACTIVITY

The principal activity of the group in the year under review was that of the running of residential care homes.

DIVIDENDS

An interim dividend of £330 per share was paid on 23 July 2025. The directors recommend that no final dividend be paid.

The total distribution of dividends for the year ended 30 November 2025 will be £ 330,000 .

DIRECTORS

The directors shown below have held office during the whole of the period from 1 December 2024 to the date of this report.

Mrs K L Rogerson

Mr P J Rogerson

DISCLOSURE IN THE STRATEGIC REPORT

The strategic report on the preceding page provides information regarding the performance, developments, and risks and uncertainties of the group.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

AUDITORS

The auditors, Ashworth Treasure Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:

Mrs K L Rogerson - Director

26 August 2026

Report of the Independent Auditors to the Members of

LP Healthcare Limited

Opinion

We have audited the financial statements of LP Healthcare Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 November 2025 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the group's and of the parent company affairs as at 30 November 2025 and of the group's profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

- | the parent company financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Members of

LP Healthcare Limited

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- |  | the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations; |

- |  | we identified the laws and regulations applicable to the group through discussions with directors and other management, and from our commercial knowledge and experience of the business sector; |

- |  | we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the group, including legislation such as Companies Act, taxation legislation, environmental and health and safety legislation etc. |

- |  | we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and |

- |  | identified laws and regulations were communicated within the audit team regularly and the team maintained alert to instances of non-compliance throughout the audit. |

We assessed the susceptibility of the group's financial statements to misstatement, including obtaining an understanding of how fraud might occur, by:

- |  | making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud;and |

- |  | considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations. |

To address the risk of fraud through management bias and override of controls, we:

- |  | performed analytical procedures to identify any unusual or unexpected relationships; |

- |  | tested journals to identify unusual transactions; |

- |  | assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and |

- |  | investigated the rationale behind significant or unusual transactions. |

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- |  | agreeing financial statement disclosures to underlying supporting documentation; |

- |  | enquiring of management as to actual and potential litigation and claims; |

- |  | reviewing correspondence with HMRC etc |

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of

LP Healthcare Limited

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Victoria Reynolds (Senior Statutory Auditor)

for and on behalf of Ashworth Treasure Limited

Statutory Auditors

17-19 Park Street

Lytham

Lancashire

FY8 5LU

26 August 2026

LP Healthcare Limited (Registered number: 12282255)

Consolidated Income Statement

for the Year Ended 30 November 2025

| 2025 |  | 2024

| Notes | £ | £ |

TURNOVER | 7,274,646 |  | 6,369,632 |  |

Cost of sales | 3,795,980 |  | 3,400,829 |  |

GROSS PROFIT | 3,478,666 |  | 2,968,803 |  |

Administrative expenses | 1,768,668 |  | 1,777,556 |  |

1,709,998 |  | 1,191,247 |  |

Other operating income | - |  | 333 |  |

OPERATING PROFIT | 6 | 1,709,998 |  | 1,191,580 |  |

Interest receivable and similar income | 14,489 |  | 8,871 |  |

1,724,487 |  | 1,200,451 |  |

Interest payable and similar expenses | 7 | 531,732 |  | 477,479 |  |

PROFIT BEFORE TAXATION | 1,192,755 |  | 722,972 |  |

Tax on profit | 8 | 450,464 |  | 276,044 |  |

PROFIT FOR THE FINANCIAL YEAR | 742,291 |  | 446,928 |  |

Profit attributable to:

Owners of the parent | 742,291 |  | 446,928 |  |

LP Healthcare Limited (Registered number: 12282255)

Consolidated Other Comprehensive Income

for the Year Ended 30 November 2025

| 2025 |  | 2024

| Notes | £ | £ |

PROFIT FOR THE YEAR | 742,291 |  | 446,928 |  |

OTHER COMPREHENSIVE INCOME | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 742,291 |  | 446,928 |  |

Total comprehensive income attributable to:

Owners of the parent | 742,291 |  | 446,928 |  |

LP Healthcare Limited (Registered number: 12282255)

Consolidated Balance Sheet

30 November 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 11 | 1,133,810 |  | 1,579,928 |  |

Tangible assets | 12 | 5,351,488 |  | 4,693,932 |  |

Investments | 13 | - |  | - |  |

6,485,298 |  | 6,273,860 |  |

CURRENT ASSETS

Stocks | 14 | 5,455 |  | 6,850 |  |

Debtors | 15 | 1,002,691 |  | 709,243 |  |

Cash at bank | 2,120,488 |  | 1,208,772 |  |

3,128,634 |  | 1,924,865 |  |

CREDITORS

Amounts falling due within one year | 16 | 1,033,758 |  | 932,889 |  |

NET CURRENT ASSETS | 2,094,876 |  | 991,976 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 8,580,174 |  | 7,265,836 |  |

CREDITORS

Amounts falling due after more than one year | 17 | (6,679,876 | ) | (5,826,228 | ) |

PROVISIONS FOR LIABILITIES | 20 | (387,044 | ) | (338,645 | ) |

NET ASSETS | 1,513,254 |  | 1,100,963 |  |

CAPITAL AND RESERVES

Called up share capital | 21 | 100 |  | 100 |  |

Retained earnings | 22 | 1,513,154 |  | 1,100,863 |  |

SHAREHOLDERS' FUNDS | 1,513,254 |  | 1,100,963 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 26 August 2026 and were signed on its behalf by:

Mrs K L Rogerson - Director

LP Healthcare Limited (Registered number: 12282255)

Company Balance Sheet

30 November 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 11 | 1,133,810 |  | 1,579,928 |  |

Tangible assets | 12 | 4,850,994 |  | 4,197,199 |  |

Investments | 13 | 500 |  | 500 |  |

5,985,304 |  | 5,777,627 |  |

CURRENT ASSETS

Debtors | 15 | 1,256,996 |  | 1,064,018 |  |

Cash at bank | 486,494 |  | 111,905 |  |

1,743,490 |  | 1,175,923 |  |

CREDITORS

Amounts falling due within one year | 16 | 605,678 |  | 792,067 |  |

NET CURRENT ASSETS | 1,137,812 |  | 383,856 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 7,123,116 |  | 6,161,483 |  |

CREDITORS

Amounts falling due after more than one year | 17 | (6,679,876 | ) | (5,817,061 | ) |

PROVISIONS FOR LIABILITIES | 20 | (266,350 | ) | (219,382 | ) |

NET ASSETS | 176,890 |  | 125,040 |  |

CAPITAL AND RESERVES

Called up share capital | 21 | 100 |  | 100 |  |

Retained earnings | 22 | 176,790 |  | 124,940 |  |

SHAREHOLDERS' FUNDS | 176,890 |  | 125,040 |  |

Company's profit for the financial year | 381,850 |  | 409,522 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 26 August 2026 and were signed on its behalf by:

Mrs K L Rogerson - Director

LP Healthcare Limited (Registered number: 12282255)

Consolidated Statement of Changes in Equity

for the Year Ended 30 November 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 December 2023 | 100 |  | 944,935 |  | 945,035 |  |

Changes in equity

Dividends | - |  | (291,000 | ) | (291,000 | ) |

Total comprehensive income | - |  | 446,928 |  | 446,928 |  |

Balance at 30 November 2024 | 100 |  | 1,100,863 |  | 1,100,963 |  |

Changes in equity

Dividends | - |  | (330,000 | ) | (330,000 | ) |

Total comprehensive income | - |  | 742,291 |  | 742,291 |  |

Balance at 30 November 2025 | 100 |  | 1,513,154 |  | 1,513,254 |  |

LP Healthcare Limited (Registered number: 12282255)

Company Statement of Changes in Equity

for the Year Ended 30 November 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 December 2023 | 100 |  | 6,418 |  | 6,518 |  |

Changes in equity

Dividends | - |  | (291,000 | ) | (291,000 | ) |

Total comprehensive income | - |  | 409,522 |  | 409,522 |  |

Balance at 30 November 2024 | 100 |  | 124,940 |  | 125,040 |  |

Changes in equity

Dividends | - |  | (330,000 | ) | (330,000 | ) |

Total comprehensive income | - |  | 381,850 |  | 381,850 |  |

Balance at 30 November 2025 | 100 |  | 176,790 |  | 176,890 |  |

LP Healthcare Limited (Registered number: 12282255)

Consolidated Cash Flow Statement

for the Year Ended 30 November 2025

| 2025 |  | 2024

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 1 | 1,834,904 |  | 1,269,846 |  |

Interest paid | (531,732 | ) | (477,479 | ) |

Tax paid | (209,276 | ) | (338,809 | ) |

Net cash from operating activities | 1,093,896 |  | 453,558 |  |

Cash flows from investing activities

Purchase of intangible fixed assets | - |  | (1,454,998 | ) |

Purchase of tangible fixed assets | (800,451 | ) | (1,366,044 | ) |

Interest received | 14,489 |  | 8,871 |  |

Net cash from investing activities | (785,962 | ) | (2,812,171 | ) |

Cash flows from financing activities

New loans in year | 1,000,000 |  | 4,328,468 |  |

Loan repayments in year | (103,233 | ) | (1,390,512 | ) |

Amount withdrawn by directors | (292,985 | ) | (329,056 | ) |

Net cash from financing activities | 603,782 |  | 2,608,900 |  |

Increase in cash and cash equivalents | 911,716 |  | 250,287 |  |

Cash and cash equivalents at beginning of year | 2 | 1,208,772 |  | 958,485 |  |

Cash and cash equivalents at end of year | 2 | 2,120,488 |  | 1,208,772 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Cash Flow Statement

for the Year Ended 30 November 2025

1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

| 2025 |  | 2024

£ | £ |

| Profit before taxation | 1,192,755 |  | 722,972 |  |

| Depreciation charges | 589,013 |  | 473,133 |  |

| Finance costs | 531,732 |  | 477,479 |  |

| Finance income | (14,489 | ) | (8,871 | ) |

2,299,011 |  | 1,664,713 |  |

| Decrease/(increase) in stocks | 1,395 |  | (2,450 | ) |

| Increase in trade and other debtors | (330,463 | ) | (114,204 | ) |

| Decrease in trade and other creditors | (135,039 | ) | (278,213 | ) |

| Cash generated from operations | 1,834,904 |  | 1,269,846 |  |

2. | CASH AND CASH EQUIVALENTS

| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

| Year ended 30 November 2025

| 30.11.25 |  | 1.12.24

£ | £ |

| Cash and cash equivalents | 2,120,488 |  | 1,208,772 |  |

| Year ended 30 November 2024

| 30.11.24 |  | 1.12.23

£ | £ |

| Cash and cash equivalents | 1,208,772 |  | 958,485 |  |

3. | ANALYSIS OF CHANGES IN NET DEBT

| At 1.12.24 | Cash flow | At 30.11.25

£ | £ | £ |

| Net cash |

| Cash at bank | 1,208,772 |  | 911,716 |  | 2,120,488 |  |

1,208,772 |  | 911,716 |  | 2,120,488 |  |

| Debt

| Debts falling due within 1 year | (113,714 | ) | (1,452 | ) | (115,166 | ) |

| Debts falling due after 1 year | (5,784,561 | ) | (895,315 | ) | (6,679,876 | ) |

(5,898,275 | ) | (896,767 | ) | (6,795,042 | ) |

| Total | (4,689,503 | ) | 14,949 |  | (4,674,554 | ) |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements

for the Year Ended 30 November 2025

1. | STATUTORY INFORMATION

| LP Healthcare Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. | STATEMENT OF COMPLIANCE

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| The financial statements have been prepared under the historical cost convention.

| Basis of consolidation

| The group financial statements consolidate the accounts of LP Healthcare Limited and its subsidiary undertakings, Abbotsfield Care Home Limited, Greenlane (Cumbria) Limited, Croft Avenue Care Home Limited, Inglewood (Cumbria) Limited and The Ferns Care Home Limited.

| Unless otherwise stated, the acquisition method of accounting has been adopted. Under this method, the results of subsidiary undertakings acquired or disposed of in the year are included in the consolidated profit and loss account from the date on which control passed.

| Related party exemption

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Turnover is derived from residents fees either private or local authority and is recognised in line with the date of stay. Any amounts paid for in advance are deferred on the balance sheet and any stays not yet paid for are accrued accordingly.

| Goodwill

| Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

| Goodwill was paid in connection with the purchase of businesses in 2020, 2021 and 2024.

| Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed five years.

| Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that assets as follows:

| Goodwill - straight line basis over 5 years

| If there is an indication that there has been significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

3. | ACCOUNTING POLICIES - continued

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

| Freehold property | - | 2% cost of buildings, 0% cost of land

| Fixtures, fittings and equipment | - | 10% on reducing balance

| Motor vehicles | - | 25% on reducing balance

| Freehold land and buildings and fixtures, fittings and equipment are stated at cost less depreciation over expected useful lives. Cost represents purchase price together with any incidental costs of acquisition.

| Investments in subsidiaries

| Investments in subsidiaries are recognised at cost. Dividends and other distributions received from the investment are recognised as income.

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Financial instruments

| The following assets and liabilities are classified as financial instruments - investments in subsidiaries, trade debtors, trade creditors, bank loans, other loans and inter-group balances.

| Investments in subsidiary undertakings are measured at cost less impairment.

| Bank loans are initially measured at the present value of future payments, discounted at a market rate of interest, and subsequently at amortised cost using the effective interest method.

| Inter-group balances (being repayable on demand), trade debtors, trade creditors and other loans are measured at the undiscounted amount of cash or other consideration expected to be paid or received.

| Financial assets are assessed at the end of each reporting period for objective evidence of impairment and if applicable recognised as appropriate.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Pension costs and other post-retirement benefits

| The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

3. | ACCOUNTING POLICIES - continued

| Subsidiary exemption from audit by parent guarantee

| The following subsidiaries included in these consolidated accounts are exempt from the relevant audit requirements of the Companies Act by virtue of S479A:

| Croft Avenue Care Home Limited |  | 13565869 |  | (England and Wales) |

| Inglewood (Cumbria) Limited |  | 13273566 |  | (England and Wales) |

| Abbotsfield Care Home Limited |  | 12282796 |  | (England and Wales) |

| Greenlane (Cumbria) Limited |  | 12326226 |  | (England and Wales) |

| The Ferns Care Home Limited |  | 15117795 |  | (England and Wales) |  |

4. | ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

| In the application of the company's accounting policies, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily available from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both.

| The sources of judgment uncertainty that have a significant effect on the amounts recognised in the financial statements are described below:

| Impairment of non-financial assets

| Non-financial assets include goodwill, investments and tangible fixed assets. The company assesses at each reporting date whether there is an indication that the carrying amount of an asset may not be recoverable. If there is such an indication then the company estimates the recoverable amount of the asset using the information available at that date. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. If the recoverable amount is less than the carrying amount, the carrying amount of an asset is impaired and it is reduced to its recoverable amount through an impairment in the statement of comprehensive income.

5. | EMPLOYEES AND DIRECTORS

| 2025 |  | 2024

£ | £ |

| Wages and salaries | 3,381,363 |  | 3,056,071 |  |

| Social security costs | 330,570 |  | 237,743 |  |

| Other pension costs | 59,031 |  | 53,060 |  |

3,770,964 |  | 3,346,874 |  |

| The average number of employees during the year was as follows:

| 2025 |  | 2024

| Office and managers | 9 |  | 11 |  |

| Nurses and carers | 106 |  | 103 |  |

| Cleaning, maintenance and catering | 34 |  | 40 |  |

149 |  | 154 |  |

| 2025 |  | 2024

£ | £ |

| Directors' remuneration | 187,824 |  | 159,565 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

6. | OPERATING PROFIT

| The operating profit is stated after charging:

| 2025 |  | 2024

£ | £ |

| Depreciation - owned assets | 142,895 |  | 138,008 |  |

| Goodwill amortisation | 446,118 |  | 335,125 |  |

| Auditors' remuneration | 24,000 |  | 30,000 |  |

| Auditors' remuneration for non audit work | 24,871 |  | 28,019 |  |

7. | INTEREST PAYABLE AND SIMILAR EXPENSES |

| 2025 |  | 2024

£ | £ |

| Bank interest | - |  | 46 |  |

| Bank loan interest | 531,278 |  | 477,365 |  |

| Other interest | 454 |  | 68 |  |

531,732 |  | 477,479 |  |

8. | TAXATION

| Analysis of the tax charge

| The tax charge on the profit for the year was as follows:

| 2025 |  | 2024

£ | £ |

| Current tax:

| UK corporation tax | 402,065 |  | 221,247 |  |

| Deferred tax | 48,399 |  | 54,797 |  |

| Tax on profit | 450,464 |  | 276,044 |  |

| UK corporation tax has been charged at 25 % (2024 - 25 %).

| Reconciliation of total tax charge included in profit and loss

| The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

| 2025 |  | 2024

£ | £ |

| Profit before tax | 1,192,755 |  | 722,972 |  |

| Profit multiplied by the standard rate of corporation tax in the UK of 25 % (2024 - 25 %) | 298,189 |  | 180,743 |  |

| Effects of:

| Expenses not deductible for tax purposes | 2,466 |  | 505 |  |

| Capital allowances in excess of depreciation | (10,119 | ) | (43,782 | ) |

| Amortisation on non qualifying assets | 111,529 |  | 83,781 |  |

| Other timing differences | 48,399 |  | 54,797 |  |

| Total tax charge | 450,464 |  | 276,044 |  |

9. | INDIVIDUAL INCOME STATEMENT

| As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

10. | DIVIDENDS

| 2025 |  | 2024

£ | £ |

| Ordinary shares of 1 each

| Interim | 330,000 |  | 291,000 |  |

11. | INTANGIBLE FIXED ASSETS

| Group

| Goodwill

£ |

| COST

| At 1 December 2024

| and 30 November 2025 | 2,584,998 |  |

| AMORTISATION

| At 1 December 2024 | 1,005,070 |  |

| Amortisation for year | 446,118 |  |

| At 30 November 2025 | 1,451,188 |  |

| NET BOOK VALUE

| At 30 November 2025 | 1,133,810 |  |

| At 30 November 2024 | 1,579,928 |  |

| Company

| Goodwill

£ |

| COST

| At 1 December 2024

| and 30 November 2025 | 2,584,998 |  |

| AMORTISATION

| At 1 December 2024 | 1,005,070 |  |

| Amortisation for year | 446,118 |  |

| At 30 November 2025 | 1,451,188 |  |

| NET BOOK VALUE

| At 30 November 2025 | 1,133,810 |  |

| At 30 November 2024 | 1,579,928 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

12. | TANGIBLE FIXED ASSETS

| Group

| Fixtures, |

| fittings |

| Freehold |  | and |  | Motor |

| property |  | equipment |  | vehicles |  | Totals

£ | £ | £ | £ |

| COST

| At 1 December 2024 | 3,998,588 |  | 1,089,632 |  | - |  | 5,088,220 |  |

| Additions | 737,647 |  | 58,807 |  | 3,997 |  | 800,451 |  |

| At 30 November 2025 | 4,736,235 |  | 1,148,439 |  | 3,997 |  | 5,888,671 |  |

| DEPRECIATION

| At 1 December 2024 | 137,983 |  | 256,305 |  | - |  | 394,288 |  |

| Charge for year | 53,940 |  | 88,705 |  | 250 |  | 142,895 |  |

| At 30 November 2025 | 191,923 |  | 345,010 |  | 250 |  | 537,183 |  |

| NET BOOK VALUE

| At 30 November 2025 | 4,544,312 |  | 803,429 |  | 3,747 |  | 5,351,488 |  |

| At 30 November 2024 | 3,860,605 |  | 833,327 |  | - |  | 4,693,932 |  |

| Company

| Fixtures, |

| fittings |

| Freehold |  | and |  | Motor |

| property |  | equipment |  | vehicles |  | Totals

£ | £ | £ | £ |

| COST

| At 1 December 2024 | 3,998,588 |  | 460,001 |  | - |  | 4,458,589 |  |

| Additions | 737,647 |  | - |  | 3,997 |  | 741,644 |  |

| At 30 November 2025 | 4,736,235 |  | 460,001 |  | 3,997 |  | 5,200,233 |  |

| DEPRECIATION

| At 1 December 2024 | 137,983 |  | 123,407 |  | - |  | 261,390 |  |

| Charge for year | 53,940 |  | 33,659 |  | 250 |  | 87,849 |  |

| At 30 November 2025 | 191,923 |  | 157,066 |  | 250 |  | 349,239 |  |

| NET BOOK VALUE

| At 30 November 2025 | 4,544,312 |  | 302,935 |  | 3,747 |  | 4,850,994 |  |

| At 30 November 2024 | 3,860,605 |  | 336,594 |  | - |  | 4,197,199 |  |

13. | FIXED ASSET INVESTMENTS

| Company

| Shares in

| group

| undertakings

£ |

| COST

| At 1 December 2024

| and 30 November 2025 | 500 |  |

| NET BOOK VALUE

| At 30 November 2025 | 500 |  |

| At 30 November 2024 | 500 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

13. | FIXED ASSET INVESTMENTS - continued

| The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

| Subsidiaries

| Abbotsfield Care Home Limited

| Registered office: 19 Park Street, Lytham, Lancashire, FY8 5LU

| Nature of business: Residential nursing home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Greenlane (Cumbria) Limited

| Registered office: 19 Park Street, Lytham, Lancashire, FY8 5LU

| Nature of business: Residential nursing home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| The Ferns Care Home Limited

| Registered office: 19 Park Street, Lytham, Lancashire FY8 5LU

| Nature of business: Residential nursing home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Inglewood (Cumbria) Limited

| Registered office: 19 Park Street, Lytham, Lancashire, FY8 5LU

| Nature of business: Residential nursing home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Croft Avenue Care Home Limited

| Registered office: 19 Park Street, Lytham, Lancashire, FY8 5LU

| Nature of business: Residential nursing home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

14. | STOCKS

| Group |

2025 | 2024 |

£ | £ |

| Stocks | 5,455 |  | 6,850 |  |

15. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Trade debtors | 58,244 |  | 48,407 |  | - |  | - |  |

| Amounts owed by group undertakings | - |  | - |  | 940,486 |  | 701,933 |  |

| Other debtors | 594,518 |  | 257,493 |  | 1,635 |  | 1,635 |  |

| Directors' loan accounts | 291,162 |  | 328,177 |  | 291,162 |  | 328,177 |  |

| Prepayments and accrued income | 58,767 |  | 75,166 |  | 23,713 |  | 32,273 |  |

1,002,691 |  | 709,243 |  | 1,256,996 |  | 1,064,018 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

16. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans and overdrafts (see note 18) | 115,166 |  | 113,714 |  | 105,999 |  | 103,714 |  |

| Trade creditors | 138,748 |  | 194,063 |  | 10,292 |  | - |  |

| Amounts owed to group undertakings | - |  | - |  | 138,592 |  | 349,584 |  |

| Tax | 327,093 |  | 134,304 |  | - |  | - |  |

| Social security and other taxes | 404 |  | 404 |  | - |  | - |  |

| Other creditors | 48,696 |  | 83,886 |  | 293,436 |  | 268,095 |  |

| Accruals and deferred income | 403,651 |  | 406,518 |  | 57,359 |  | 70,674 |  |

1,033,758 |  | 932,889 |  | 605,678 |  | 792,067 |  |

17. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans (see note 18) | 6,679,876 |  | 5,784,561 |  | 6,679,876 |  | 5,775,394 |  |

| Other creditors | - |  | 41,667 |  | - |  | 41,667 |  |

6,679,876 |  | 5,826,228 |  | 6,679,876 |  | 5,817,061 |  |

18. | LOANS

| An analysis of the maturity of loans is given below:

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Amounts falling due within one year or on | demand: |

| Bank loans | 115,166 |  | 113,714 |  | 105,999 |  | 103,714 |  |

| Amounts falling due between one and two | years: |

| Bank loans - 1-2 years | 2,565,097 |  | 120,110 |  | 2,565,097 |  | 110,943 |  |

| Amounts falling due between two and five | years: |

| Bank loans - 2-5 years | 4,114,779 |  | 5,664,451 |  | 4,114,779 |  | 5,664,451 |  |

19. | SECURED DEBTS

| The following secured debts are included within creditors:

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans | 6,795,042 |  | 5,934,171 |  | 6,785,786 |  | 5,934,171 |  |

| The bank loans are secured by fixed and floating charges over the group's properties and assets, together with debentures over all assets, cross guarantees with subsidiary companies and a personal guarantee from the directors.

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

20. | PROVISIONS FOR LIABILITIES

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Deferred tax | 387,044 |  | 338,645 |  | 266,350 |  | 219,382 |  |

| Group

| Deferred |

| tax |

£ |

| Balance at 1 December 2024 | 338,645 |  |

| Provided during year | 48,399 |  |

| Balance at 30 November 2025 | 387,044 |  |

| Company

| Deferred |

| tax |

£ |

| Balance at 1 December 2024 | 219,382 |  |

| Provided during year | 46,968 |  |

| Balance at 30 November 2025 | 266,350 |  |

| The deferred tax provision for both the group and the company arises solely as a result of capital allowances in excess of depreciation.

21. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | 1 | 100 |  | 100 |  |

22. | RESERVES

| Group

| Retained

| earnings

£ |

| At 1 December 2024 | 1,100,863 |  |

| Profit for the year | 742,291 |  |

| Dividends | (330,000 | ) |

| At 30 November 2025 | 1,513,154 |  |

| Company

| Retained

| earnings

£ |

| At 1 December 2024 | 124,940 |  |

| Profit for the year | 381,850 |  |

| Dividends | (330,000 | ) |

| At 30 November 2025 | 176,790 |  |

LP Healthcare Limited (Registered number: 12282255)

Notes to the Consolidated Financial Statements - continued

for the Year Ended 30 November 2025

23. | CAPITAL COMMITMENTS

| The group has spent £610,000 in the year building an extension to one of its existing homes which it is committed to complete. The total expected cost of the extension is £1.2m. A bank loan was taken out in the year to cover this cost.

24. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

| The following advances and credits to directors subsisted during the years ended 30 November 2025 and 30 November 2024:

2025 | 2024 |

£ | £ |

| Mrs K L Rogerson and Mr P J Rogerson

| Balance outstanding at start of year | 328,177 |  | 290,121 |  |

| Amounts advanced | 292,985 |  | 329,056 |  |

| Amounts repaid | (330,000 | ) | (291,000 | ) |

| Amounts written off | - |  | - |  |

| Amounts waived | - |  | - |  |

| Balance outstanding at end of year | 291,162 |  | 328,177 |  |

| Interest was charged at the official rate of interest where appropriate.

| The directors of the company have provided a personal guarantee in respect of a bank loan facility amounting to £550,000. No amounts have been paid in respect of this guarantee.

25. | RELATED PARTY DISCLOSURES

| Entities with control, joint control or significant influence over the | entity |

| Included in debtors at 30 November 2025 are the following net amounts owed to the group by companies related by virtue of common control:

| Kingsfield (Cumbria) Limited £64,805 (2024: £23,494).

| P H Care Limited £471,774 (2024: £223,273).

| Knowle Care Home Limited £52,042 (2024 creditor: £32,364).

| Stanfield Nursing Home Limited £2,271 (2024: £0).

| All related party loans are interest free, unsecured and repayable on demand.

| The group's key management personel are considered to be the directors. Their compensation during the year is shown in note 5.

26. | ULTIMATE CONTROLLING PARTY

| There is no ultimate controlling party.